Related Experiment Video
Updated: Jul 9, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from
Jasminka Sterjovski1, Melissa J Churchill, Anne Ellett
1Macfarlane Burnet Institute for Medical Research & Public Health, Melbourne, Victoria, Australia. Jasminka@burnet.edu.au
Background:
CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively.
Results:
Compared to PA-R5 Envs, A-R5 Envs had enhanced fusogenicity in quantitative cell-cell fusion assays, and reduced sensitivity to inhibition by the fusion inhibitor T-20. Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. N362 was associated with enhanced fusogenicity, faster entry kinetics, and increased sensitivity of Env-pseudotyped reporter viruses to neutralization by the CD4bs-directed Env mAb IgG1b12. Mutagenesis studies showed N362 contributes to enhanced fusogenicity of most A-R5 Envs. Molecular models indicate N362 is located adjacent to the CD4 binding loop of gp120, and suggest N362 may enhance fusogenicity by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env structure.
Conclusion:
Enhanced fusogenicity is a phenotype of the A-R5 Envs studied, which was associated with the presence of N362, enhanced HIV-1 entry kinetics and increased CD4bs exposure in gp120. N362 contributes to fusogenicity of R5 Envs in a strain dependent manner. Our studies suggest enhanced fusogenicity of A-R5 Envs may contribute to CD4+ T-cell loss in subjects who progress to AIDS whilst harbouring R5 HIV-1 variants. N362 may contribute to this effect in some individuals.
Insights
Enhanced fusogenicity in AIDS-causing HIV-1 variants is linked to N362, a glycosylation site near the CD4-binding site. This feature may contribute to CD4+ T-cell loss in individuals with AIDS.
Area of Science:
- Virology
- Immunology
Background:
- CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) causes CD4+ T-cell loss, but pathogenicity mechanisms are unclear.
- Understanding envelope glycoprotein (Env) determinants is crucial for R5 HIV-1 pathogenicity.
Purpose of the Study:
- Characterize R5 Envs from asymptomatic and AIDS patients to identify determinants of pathogenicity.
- Investigate the role of specific Env features in HIV-1 pathogenesis.
Main Methods:
- Analyzed 37 full-length R5 Envs from pre-AIDS (PA) and AIDS (A) patients.
- Performed quantitative cell-cell fusion assays and sequence analysis.
- Utilized mutagenesis studies and molecular modeling.
Main Results:
- AIDS (A)-R5 Envs exhibited enhanced fusogenicity and reduced sensitivity to T-20 compared to pre-AIDS (PA)-R5 Envs.
- The N-linked glycosylation site N362 was more frequent in A-R5 Envs and associated with enhanced fusogenicity and faster entry kinetics.
- N362 was linked to increased sensitivity to neutralization by the CD4-binding site (CD4bs)-directed mAb IgG1b12.
Conclusions:
- Enhanced fusogenicity of A-R5 Envs, associated with N362, contributes to HIV-1 entry kinetics and CD4bs exposure.
- N362 influences R5 Env fusogenicity in a strain-dependent manner.
- Enhanced fusogenicity of A-R5 Envs, potentially mediated by N362, may contribute to CD4+ T-cell loss in AIDS progression.
More Related Videos
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
10:50Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010